Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Indian J Ophthalmol ; 72(3): 427-431, 2024 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-38146971

RESUMO

PURPOSE: To study and compare the efficacy and safety profile of Rho-kinase inhibitor (netarsudil 0.02%) and prostaglandin analog (bimatoprost 0.01%) both as monotherapy and in combination. DESIGN: Prospective, randomized, monocentric, open-label clinical trial. METHODS: Patients ≥20 years of age with primary open-angle glaucoma or ocular hypertension (IOP >21 mmHg) were recruited and randomized to receive either netarsudil 0.02%, netarsudil 0.02% + bimatoprost 0.01%, or bimatoprost 0.01% once daily for a period of 12 weeks. IOP and side effects were documented at 4, 8, and 12 weeks. RESULTS: The mean treated IOP ranged 17.51-18.57 mmHg for netarsudil, 15.80-16.46 mmHg for bimatoprost, and 14.00-14.87 mmHg for the combination therapy group. The mean IOP reduction from baseline at 4, 8, and 12 weeks was found to be statistically significant ( P < 0.001) in all three groups. The safety profile of netarsudil/bimatoprost combination was consistent with each constituent individually. The only frequently observed ocular adverse event was conjunctival hyperemia, which was seen mostly in netarsudil and netarsudil + bimatoprost groups ( P < 0.001). CONCLUSION: The IOP-lowering effect of netarsudil 0.02% once daily is non-inferior to bimatoprost 0.01% in patients with POAG and ocular hypertension with acceptable ocular safety, and the combination therapy achieved a higher IOP-lowering effect. This group of medications can be a useful adjunct in patients on maximal therapy.


Assuntos
Benzoatos , Glaucoma de Ângulo Aberto , Glaucoma , Hipertensão Ocular , beta-Alanina/análogos & derivados , Humanos , Lactente , Bimatoprost/uso terapêutico , Glaucoma de Ângulo Aberto/tratamento farmacológico , Estudos Prospectivos , Pressão Intraocular , Anti-Hipertensivos/uso terapêutico , Hipertensão Ocular/tratamento farmacológico , Glaucoma/tratamento farmacológico , Resultado do Tratamento , Soluções Oftálmicas
2.
Nepal J Ophthalmol ; 8(15)2016 01.
Artigo em Inglês | MEDLINE | ID: mdl-28242894

RESUMO

BACKGROUND: Ophthalmomyiasis is a rare entity seen mainly in immunocompromised host with neglected wounds under poor hygienic conditions. CASE: We report a case of extreme ophthalmomyiasis with extensive facial and scalp involvement in an old rural inhabitant following evisceration. CONCLUSION: Proper wound care and personal hygiene are of paramount importance for good wound healing.


Assuntos
Evisceração do Olho/efeitos adversos , Infecções Oculares Parasitárias/etiologia , Miíase/etiologia , Complicações Pós-Operatórias/parasitologia , Animais , Dípteros , Dermatoses Faciais/parasitologia , Humanos , Higiene , Larva , Dermatoses do Couro Cabeludo/parasitologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...